20,455 Shares in Journey Medical Co. (NASDAQ:DERM) Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP acquired a new stake in Journey Medical Co. (NASDAQ:DERM) during the 4th quarter, Holdings Channel reports. The fund acquired 20,455 shares of the company’s stock, valued at approximately $80,000.

Insider Buying and Selling

In other Journey Medical news, CEO Claude Maraoui sold 18,147 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total value of $93,094.11. Following the transaction, the chief executive officer now owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. The trade was a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 113,522 shares of company stock worth $589,229. 15.03% of the stock is owned by corporate insiders.

Journey Medical Trading Down 2.4%

Shares of DERM stock opened at $6.93 on Monday. The company has a market cap of $160.11 million, a P/E ratio of -7.37 and a beta of 0.86. The stock has a 50 day simple moving average of $6.44 and a two-hundred day simple moving average of $5.42. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical Co. has a fifty-two week low of $3.20 and a fifty-two week high of $8.24.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.06. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The firm had revenue of $13.14 million during the quarter, compared to the consensus estimate of $12.05 million. Research analysts forecast that Journey Medical Co. will post -1.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DERM has been the topic of a number of recent research reports. Industrial Alliance Securities set a $10.50 price target on Journey Medical in a research note on Thursday, March 27th. Alliance Global Partners reaffirmed a “buy” rating on shares of Journey Medical in a research note on Thursday, March 27th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $9.88.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.